Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
Phase 1
20
about 3.3 years
18+
1 site in CA
What this study is about
This trial is testing a treatment called [18F]-αvβ6-BP as an imaging agent for lung cancer with brain metastases. The goal is to see if [18F]-αvβ6-BP PET/CT can accurately detect and assess the extent of disease in patients with metastatic NSCLC, including those with brain metastases.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take [18F]-αvβ6-BP
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: [18F]-αvβ6-BP PET/CT imaging compared to immunohistochemistry
Secondary: Comparison of standard-of-care MRI and [18F]-αvβ6-BP PET/CT imaging, Comparison of standard-of-care MRI brain and [18F]-FDG PET/CT and [18F]-αvβ6-BP PET/CT imaging post treatment, Comparison of standard-of-care [18F]-FDG PET/CT and [18F]-αvβ6-BP PET/CT imaging
Oncology